Neon Therapeutics begins enrolment for inaugural trial of cancer vaccine NEO-PV-01
US-based immuno-oncology company Neon Therapeutics has begun enrolment for its inaugural trial of NEO-PV-01 to treat cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - November 21, 2016 Category: Pharmaceuticals Source Type: news

Sanofi Genzyme begins Phase III COMET clinical trial of neoGAA to treat Pompe disease in UK
Sanofi Genzyme has begun enrolment and dosed the first UK patient for its pivotal Phase III COMET clinical trial of neoGAA to treat Pompe disease. (Source: Drug Development Technology)
Source: Drug Development Technology - November 21, 2016 Category: Pharmaceuticals Source Type: news

M & As this week: Northsight Capital, GL Capital and ABG Management, Tonghua Golden Horse Pharmaceutical Industry
Northsight Capital plans to acquire Stargreen Holdings to expand its business and presence in the cannabis industry. (Source: Drug Development Technology)
Source: Drug Development Technology - November 18, 2016 Category: Pharmaceuticals Source Type: news

Report: Cannabinoid-based products emerging as promising pharmaceutical ingredients
The market for synthetic cannabinoid products is growing despite legal restrictions, says a white paper from GBI Research. (Source: Drug Development Technology)
Source: Drug Development Technology - November 18, 2016 Category: Pharmaceuticals Source Type: news

Deals this week: Pfizer, Peakdale Molecular, Selexis
Pfizer and National Cancer Institute have entered a co-operative research and development (R&D) agreement to develop novel immunotherapy candidates targeting multiple cancers. (Source: Drug Development Technology)
Source: Drug Development Technology - November 18, 2016 Category: Pharmaceuticals Source Type: news

Summit begins enrolment for Phase II PhaseOut DMD trial of ezutromid to treat DMD
UK-based clinical-stage drug discovery and development company Summit Therapeutics has begun enrolment in the US for its Phase II PhaseOut DMD clinical trial of ezutromid to treat Duchenne muscular dystrophy (DMD). (Source: Drug Development Technology)
Source: Drug Development Technology - November 18, 2016 Category: Pharmaceuticals Source Type: news

Imara initiates Phase I clinical study of IMR-687 to treat sickle-cell disease
US-based biotechnology company Imara has initiated its Phase I clinical study of IMR-687 to treat patients with sickle-cell disease and other haemoglobinopathies. (Source: Drug Development Technology)
Source: Drug Development Technology - November 18, 2016 Category: Pharmaceuticals Source Type: news

Invokamet XR for the Treatment of Type 2 Diabetes in Adults
Developed by Janssen Pharmaceuticals, Invokamet XR (Canagliflozin / Metformin Hydrochloride Extended Release) is indicated for the treatment of Type 2 diabetes in adults. (Source: Drug Development Technology)
Source: Drug Development Technology - November 17, 2016 Category: Pharmaceuticals Source Type: news

EMA seeks to revise guidelines on first-in-human clinical trials
The European Medicines Agency (EMA), along with the European Commission and the Member States of the European Union (EU), has proposed changes in guidelines for first-in-human clinical trials. (Source: Drug Development Technology)
Source: Drug Development Technology - November 17, 2016 Category: Pharmaceuticals Source Type: news

Boehringer Ingelheim reports positive Phase III RE-VERSE AD study updates of Praxbind
Boehringer Ingelheim has reported positive updated results from its ongoing Phase III RE-VERSE AD study of Praxbind (idarucizumab) to treat patients in emergency settings. (Source: Drug Development Technology)
Source: Drug Development Technology - November 17, 2016 Category: Pharmaceuticals Source Type: news

Amgen reports positive Phase III GLAGOV trial of Repatha to treat coronary heart disease
Amgen has reported positive results from its Phase III GLAGOV trial of Repatha (evolocumab) added to optimised statin therapy in treating statistically significant regression of atherosclerosis in patients with coronary artery disease (CAD). (Source: Drug Development Technology)
Source: Drug Development Technology - November 17, 2016 Category: Pharmaceuticals Source Type: news

Sartorius-Biopharmaceutical Laboratory Equipment and Integrated Bioprocess Services
Sartorius is a worldwide leading provider of laboratory and process technologies. Our range of products and services allow customers involved in biopharmaceutical production and labs to efficiently use intricate and quality-critical processes in a co … (Source: Drug Development Technology)
Source: Drug Development Technology - November 16, 2016 Category: Pharmaceuticals Source Type: news

Mallinckrodt begins enrolment for Phase IV study of HP Acthar Gel to treat SLE
Irish biopharmaceutical company Mallinckrodt has begun enrolment for its Phase IV clinical study of HP Acthar Gel to treat systemic lupus erythematosus (SLE) patients with persistently active disease. (Source: Drug Development Technology)
Source: Drug Development Technology - November 16, 2016 Category: Pharmaceuticals Source Type: news

Stealth BioTheraputics begins Phase I ReCLAIM study of elamipretide to treat AMD
US-based biopharmaceutical company Stealth BioTherapeutics has initiated its Phase I ReCLAIM study of elamipretide to treat intermediate, dry age-related macular degeneration (AMD). (Source: Drug Development Technology)
Source: Drug Development Technology - November 16, 2016 Category: Pharmaceuticals Source Type: news

Bayer announces Phase III CHICO study of Nifurtimox to treat Chagas disease
Bayer has announced a Phase III CHICO study of Nifurtimox to treat children of all age groups with Chagas disease. (Source: Drug Development Technology)
Source: Drug Development Technology - November 16, 2016 Category: Pharmaceuticals Source Type: news

Braeburn and Camurus report positive top-line results from Phase III trial of CAM2038 for opioid use disorder
Pharmaceutical companies Braeburn and Camurus have reported positive top-line results from a pivotal Phase III trial of buprenorphine (CAM2038) to treat moderate-to-severe opioid use disorder. (Source: Drug Development Technology)
Source: Drug Development Technology - November 15, 2016 Category: Pharmaceuticals Source Type: news

Amgen and UCB report positive Phase III BRIDGE study results of romosozumab to treat osteoporosis
Amgen and UCB have reported positive results from its Phase III BRIDGE study of romosozumab for treating men with osteoporosis. (Source: Drug Development Technology)
Source: Drug Development Technology - November 15, 2016 Category: Pharmaceuticals Source Type: news

Neuren Pharmaceuticals completes enrolment for Phase II trial of trofinetide to treat Rett syndrome
US-based biopharmaceutical company Neuren has completed enrolment for its Phase II clinical trial of trofinetide in pediatric Rett syndrome. (Source: Drug Development Technology)
Source: Drug Development Technology - November 15, 2016 Category: Pharmaceuticals Source Type: news

Elcelyx Therapeutics reports positive Phase IIb study results of Metformin DR to treat type 2 diabetes
Elcelyx Therapeutics has reported that its Phase 2b dose-ranging study met the primary endpoint of indicating a statistically significant reduction in HbA1c at 16 weeks with Metformin Delayed Release (Metformin DR) compared with placebo in subjects w … (Source: Drug Development Technology)
Source: Drug Development Technology - November 14, 2016 Category: Pharmaceuticals Source Type: news

GCA trial's new data indicates 56% of people treated with RoActemra achieved steroid-free disease remission
New data from giant-cell arteritis (GCA) trial indicates that 56% of people treated with RoActemra (tocilizumab) achieved steroid-free disease remission at one year, compared with only 14% given the present standard of care with steroids alone. (Source: Drug Development Technology)
Source: Drug Development Technology - November 14, 2016 Category: Pharmaceuticals Source Type: news

Washington University School of Medicine in St. Louis to begin clinical trial of dantrolene to treat Wolfram syndrome
The Washington University School of Medicine in St. Louis is beginning a new clinical trial of the drug known as dantrolene to treat patients with Wolfram syndrome. (Source: Drug Development Technology)
Source: Drug Development Technology - November 14, 2016 Category: Pharmaceuticals Source Type: news

RegeneRx begins patient enrolment in US for ARISE-2 trial of RGN-259 to treat dry eye syndrome
US-based clinical-stage drug development company RegeneRx has begun patient enrolment in its Phase III ARISE-2 trial of RGN-259 (Thymosin beta 4) to treat dry eye syndrome, neurotrophic keratopathy (NK), and other corneal disorders. (Source: Drug Development Technology)
Source: Drug Development Technology - November 11, 2016 Category: Pharmaceuticals Source Type: news

Bristol-Myers Squibb and Infinity collaborate to test Opdivo and IPI-549 combination
Bristol-Myers Squibb Company (BMY) and Infinity Pharmaceuticals will collaborate to conduct a clinical study of Bristol-Myers Squibb ’s Opdivo in combination with Infinity’s IPI-549 to treat advanced solid tumours. (Source: Drug Development Technology)
Source: Drug Development Technology - November 11, 2016 Category: Pharmaceuticals Source Type: news

M & As this week: Sichuan Kelun Pharma, CiToxLAB
Sichuan Kelun Pharma has announced its intention to acquire stakes in two pharmaceutical companies, one based in Guangxi and another in Changshu. (Source: Drug Development Technology)
Source: Drug Development Technology - November 11, 2016 Category: Pharmaceuticals Source Type: news

Deals this week: GeoVax Labs, Yisheng Biopharma, Oryzon Genomics
GeoVax Labs and ViaMune have signed a co-development agreement for cancer immunotherapy programmes. (Source: Drug Development Technology)
Source: Drug Development Technology - November 11, 2016 Category: Pharmaceuticals Source Type: news

Report: Alkermes ’ ALKS-5461 to emerge as key player in major depressive disorder market
Positive results from a Phase III study on Alkermes ’ ALKS-5461 shows promise towards the development of a new treatment for major depressive disorder (MDD), according to a report by GlobalData. (Source: Drug Development Technology)
Source: Drug Development Technology - November 11, 2016 Category: Pharmaceuticals Source Type: news

Imago BioSciences begins enrolment for Phase I/II study of IMG-7289 to treat AML and MDS
US-based pharmaceutical company Imago BioSciences has begun enrolment for its Phase I/II study of IMG-7289 to treat high-risk acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS). (Source: Drug Development Technology)
Source: Drug Development Technology - November 10, 2016 Category: Pharmaceuticals Source Type: news

Seattle Genetics and Takeda Pharmaceutical complete enrolment for Phase III ECHELON-2 trial of ADCETRIS
Seattle Genetics and Takeda Pharmaceutical have completed patient enrolment for the Phase III ECHELON-2 clinical trial of ADCETRIS (brentuximab vedotin) to treat CD30-positive mature T-cell lymphoma (MTCL). (Source: Drug Development Technology)
Source: Drug Development Technology - November 10, 2016 Category: Pharmaceuticals Source Type: news

Malvern Announce Web Seminar for Developers and Manufacturers of Battery Slurries
Advancements in portable electronic devices such as mobile phones and laptops has increased demand for advances in battery technology. (Source: Drug Development Technology)
Source: Drug Development Technology - November 9, 2016 Category: Pharmaceuticals Source Type: news

Immunovative Therapies initiates Phase IIb study of cancer vaccine to treat metastatic colorectal cancer
Immunovative Therapies' subsidiary ImmunoCare has reported the start of a Phase IIb study of CryoVax, a next-generation immunotherapy cancer vaccine product for patients with chemotherapy-refractory (third line) metastatic colorectal cancer (mCRC). (Source: Drug Development Technology)
Source: Drug Development Technology - November 9, 2016 Category: Pharmaceuticals Source Type: news

Eisai begins two Phase III clinical studies of perampanel to treat seizures and Lennox-Gastaut Syndrome
Eisai begins two Phase III clinical studies of perampanel in children with inadequately controlled partial-onset (focal) seizures or primary generalised tonic-clonic (PGTC) seizures and Lennox-Gastaut Syndrome related seizures. (Source: Drug Development Technology)
Source: Drug Development Technology - November 9, 2016 Category: Pharmaceuticals Source Type: news

WRAIR begins clinical trial of Zika vaccine in humans
The Walter Reed Army Institute of Research (WRAIR) Clinical Trial Center, part of the US Department of Defense (DoD), has initiated the first of the five early stage clinical trials of the Zika Purified Inactivated Virus (ZPIV) vaccine to generate an … (Source: Drug Development Technology)
Source: Drug Development Technology - November 9, 2016 Category: Pharmaceuticals Source Type: news

Malvern Hosts Webinar on Using a Diffusion Interaction Parameter Measurement for Taylor Dispersion Analysis
Malvern has announced it will host a webinar discussing the use of a diffusion interaction parameter (kD) measurement for the Taylor dispersion analysis in early stages of development. (Source: Drug Development Technology)
Source: Drug Development Technology - November 8, 2016 Category: Pharmaceuticals Source Type: news

Astareal reports positive results from study of astaxanthin to treat mental and physical fatigue
Japanese-based Astareal has reported positive results from its study of astaxanthin in treating mental and physical fatigue. (Source: Drug Development Technology)
Source: Drug Development Technology - November 8, 2016 Category: Pharmaceuticals Source Type: news

Actelion reports positive Merit study results of macitentan to treat pulmonary hypertension
Swiss bio-technology company Actelion has reported positive results from its macitentan in the treatment of Inoperable chronic thromboembolic pulmonary hypertension (Merit) study of macitentan in patients with inoperable chronic thromboembolic pulmon … (Source: Drug Development Technology)
Source: Drug Development Technology - November 8, 2016 Category: Pharmaceuticals Source Type: news

October ’s top stories: Eurocine Vaccines initiated influenza vaccine study, IVF usage led to conceiving male child
Eurocine Vaccines initiated a Phase I/II influenza vaccine study and a new study suggested in-vitro fertilisation increases the chances of conceiving a male child. Drugdevelopment-technology.com wraps up the key headlines from October 2016. (Source: Drug Development Technology)
Source: Drug Development Technology - November 7, 2016 Category: Pharmaceuticals Source Type: news

Neovacs begins enrolment for Phase IIb study of IFNalpha Kinoid to treat systemic lupus erythematosus
Neovacs has begun enrolment for its international Phase IIb clinical study of IFNalpha Kinoid to treat systemic lupus erythematosus (SLE). (Source: Drug Development Technology)
Source: Drug Development Technology - November 7, 2016 Category: Pharmaceuticals Source Type: news

Mereo BioPharma reports positive Phase I interaction study of BCT-197 to treat AECOPD
UK-based Mereo BioPharma has reported a positive outcome from its Phase 1 drug interaction study with acumapimod, an active compound in the company ’s novel p38 MAP kinase inhibitor BCT-197. (Source: Drug Development Technology)
Source: Drug Development Technology - November 7, 2016 Category: Pharmaceuticals Source Type: news

Sanofi Genzyme begins enrolment in Phase II/III ASCEND clinical trial of olipudase alfa in UK
Sanofi Genzyme has begun enrolment for its pivotal Phase II/III ASCEND clinical trial of olipudase alfa to treat non-neurological manifestations of acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease type B (NPD B). (Source: Drug Development Technology)
Source: Drug Development Technology - November 7, 2016 Category: Pharmaceuticals Source Type: news

Eli Lilly and Incyte report positive data from Phase III RA-BEACON trial of baricitinib to treat rheumatoid arthritis
Eli Lilly and Company and Incyte Corporation announced that new data from RA-BEACON, a phase 3 study of baricitinib in the treatment of moderate-to-severe rheumatoid arthritis (RA), indicated baricitinib had demonstrated significant improvement in pa … (Source: Drug Development Technology)
Source: Drug Development Technology - November 4, 2016 Category: Pharmaceuticals Source Type: news

M & As this week: Signal Genetics, Celldex Therapeutics
US-based molecular diagnostic company Signal Genetics is set to merge with clinical-stage biopharmaceutical company miRagen Therapeutics, with the boards of directors of both companies having unanimously approved the merger that will create a clinica … (Source: Drug Development Technology)
Source: Drug Development Technology - November 4, 2016 Category: Pharmaceuticals Source Type: news

Deals this week: miRagen Therapeutics, Zhongyuan Union Cell, Health Advance
US-based biopharmaceutical company miRagen Therapeutics plans to raise $40m through private placement of its common stock shares with the help of placement agent Wedbush PacGrow. (Source: Drug Development Technology)
Source: Drug Development Technology - November 4, 2016 Category: Pharmaceuticals Source Type: news

Baxter begins enrolment for Phase III trial of citrate anticoagulant and renal replacement solution combination
US healthcare company Baxter has begun enrolment for its Phase III clinical trial of a drug that is a combination of citrate anticoagulant and renal replacement solution to treat acute kidney-injury patients receiving continuous renal replacement the … (Source: Drug Development Technology)
Source: Drug Development Technology - November 4, 2016 Category: Pharmaceuticals Source Type: news

Malvern Announce Webinar to Discuss Rheological Requirements of Paintings and Coatings
Malvern will be hosting a webinar to discuss the rheological requirements of paintings and coatings, as well as how they can be measured using a rotational rheometer. (Source: Drug Development Technology)
Source: Drug Development Technology - November 3, 2016 Category: Pharmaceuticals Source Type: news

DNAtrix begins Phase II trial of DNX-2401 and KEYTRUDA to treat recurrent glioblastoma
DNAtrix has announced that the first patients have been treated in a multicentre Phase 2 trial investigating its oncolytic adenovirus, DNX-2401, in combination with KEYTRUDA (pembrolizumab), Merck ’s anti-PD-1 therapy, in patients suffering with recur… (Source: Drug Development Technology)
Source: Drug Development Technology - November 3, 2016 Category: Pharmaceuticals Source Type: news

Theravance Biopharma reports positive data from trials conducted on VIBATIV
US-based biopharmaceutical company Theravance has reported positive results from trials of VIBATIV (telavancin) in treating osteomyelitis and combat methicillin-resistant staphylococcus aureus (MRSA) pathogens. (Source: Drug Development Technology)
Source: Drug Development Technology - November 3, 2016 Category: Pharmaceuticals Source Type: news

Eisai and Purdue Pharma begin Phase II study of lemborexant to treat irregular sleep-wake rhythm disorder
Eisai and Purdue Pharma have begun the Phase II clinical study of lemborexant (E2006) to treat patients with mild-to-moderate Alzheimer's disease (AD) who suffer from irregular sleep-wake rhythm disorder (ISWRD). (Source: Drug Development Technology)
Source: Drug Development Technology - November 2, 2016 Category: Pharmaceuticals Source Type: news

Cellceutix begins Phase IIb clinical trial of Prurisol to treat psoriasis
US-based clinical stage biopharmaceutical company Cellceutix has begun its Phase IIb clinical trial of Prurisol to treat moderate-to-severe chronic plaque psoriasis. (Source: Drug Development Technology)
Source: Drug Development Technology - November 2, 2016 Category: Pharmaceuticals Source Type: news

Ergomed and Asarina to jointly conduct Phase IIb trial of Sepranolone to treat premenstrual dysphoric disorder
Clinical trial services and drug development company Ergomed has entered a co-development agreement with Asarina Pharma to conduct the Phase IIb clinical trial of Sepranolone (UC1010) to treat premenstrual dysphoric disorder (PMDD). (Source: Drug Development Technology)
Source: Drug Development Technology - November 2, 2016 Category: Pharmaceuticals Source Type: news

Wellcome recommends clinical trial network for efficient and cheap drug development
UK-based biomedical research charity the Wellcome Trust has released a report suggesting creation of a clinical trial network to facilitate a cheap and efficient way of developing drugs for drug-resistant infections. (Source: Drug Development Technology)
Source: Drug Development Technology - November 1, 2016 Category: Pharmaceuticals Source Type: news